DR-311 Whole Genome Sequencing for exploratory investigation of actionable mutations in AYA patients

Cancer in Adolescents and Young Adults (AYA, 18-39 years) differs potentially from other age groups in that AYA patients can develop a mix of paediatric cancers, adult cancers (>39 years), and age group-specific cancers. Yet, there is no age group-specific approach for treatment and AYA cancer patients are typically treated similar to older cancer patients without specific evidence that this is the most effective approach. The pathogenesis of AYA cancers could in part be initiated by inherited mutations, and specific activating mutations that drive development of cancer. It is not known how often these mutations occur and for what AYA tumour types the spectrum reflects paediatric, adult, AYA-specific or a mix of these cancers. Also, potential clinical consequences for ‘targeted therapy’ will be investigated quantitatively and qualitatively.

Jeffrey van Putten, Hartwig Medical Foundation, The Netherlands